Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine
A Rahmann,
T Wienecke,
JM Hansen,
J Fahrenkrug,
J Olesen,
M Ashina,
Corresponding Author
A Rahmann
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Department of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, Denmark, and
Alexandra Rahmann, MD, Department of Neurology, University Hospital Münster, University of Münster, Albert-Schweitzer Street 33, 48149 Münster, Germany. Tel. + 49 25 1591 4879, fax + 49 25 1591 5286, e-mail [email protected]Search for more papers by this authorT Wienecke
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorJM Hansen
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorJ Fahrenkrug
Department of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, Denmark, and
Search for more papers by this authorJ Olesen
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorM Ashina
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorA Rahmann,
T Wienecke,
JM Hansen,
J Fahrenkrug,
J Olesen,
M Ashina,
Corresponding Author
A Rahmann
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Department of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, Denmark, and
Alexandra Rahmann, MD, Department of Neurology, University Hospital Münster, University of Münster, Albert-Schweitzer Street 33, 48149 Münster, Germany. Tel. + 49 25 1591 4879, fax + 49 25 1591 5286, e-mail [email protected]Search for more papers by this authorT Wienecke
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorJM Hansen
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorJ Fahrenkrug
Department of Clinical Biochemistry, Bispebjerg Hospital, University of Copenhagen, Denmark, and
Search for more papers by this authorJ Olesen
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorM Ashina
Danish Headache Centre, Department of Neurology, Glostrup Hospital and
Search for more papers by this authorAbstract
We hypothesized that intravenous infusion of the parasympathetic transmitter, vasoactive intestinal peptide (VIP), might induce migraine attacks in migraineurs. Twelve patients with migraine without aura were allocated to receive 8 pmol kg−1 min−1 VIP or placebo in a randomized, double-blind crossover study. Headache was scored on a verbal rating scale (VRS), mean blood flow velocity in the middle cerebral artery (Vmean MCA) was measured by transcranial Doppler ultrasonography, and diameter of the superficial temporal artery (STA) by high-frequency ultrasound. None of the subjects reported a migraine attack after VIP infusion. VIP induced a mild immediate headache (maximum 2 on VRS) compared with placebo (P = 0.005). Three patients reported delayed headache (3–11 h after infusion) after VIP and two after placebo (P = 0.89). Vmean MCA decreased (16.3 ± 5.9%) and diameter of STA increased significantly after VIP (45.9 ± 13.9%). VIP mediates a marked dilation of cranial arteries, but does not trigger migraine attacks in migraineurs. These data provide further evidence against a purely vascular origin of migraine.
References
- 1 Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703–9.
- 2 Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384: 560–4.
- 3 Messlinger K, Ellrich J. Meningeal nociception: electrophysiological studies related to headache and referred pain. Microsc Res Tech 2001; 53: 129–37.
- 4 Penfield W, McNaughton M. Dural headache and innervation of the dura mater. Neurol Psychiatry 1940; 44: 43–75.
- 5 Ray BS, Wolff HG. Experimental studies on headache. Pain-sensitive structures of the head and significance in headache. Arch Surg 1940; 41: 813–56.
- 6 Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104–10.
- 7 Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1994; 1: 73–80.
- 8 Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54–61.
- 9 Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005; 128: 932–9.
- 10 Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106: 461–70.
- 11 Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004; 24: 611–22.
- 12 Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med 2002; 346: 257–70.
- 13 Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003; 60: 935–40.
- 14 Barbanti P, Fabbrini G, Pesare M, Vanacore N, Cerbo R. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 2002; 22: 256–9.
- 15 Dora B. Migraine with cranial autonomic features and strict unilaterality. Cephalalgia 2003; 23: 561–2.
- 16 Burstein R, Jakubowski M. Unitary hypothesis for multiple triggers of the pain and strain of migraine. J Comp Neurol 2005; 493: 9–14.
- 17 Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004; 110: 675–80.
- 18 Modin A, Weitzberg E, Lundberg JM. Nitric oxide regulates peptide release from parasympathetic nerves and vascular reactivity to vasoactive intestinal polypeptide in vivo. Eur J Pharmacol 1994; 261: 185–97.
- 19 Yu JG, Kimura T, Chang XF, Lee TJ. Segregation of VIPergic-nitric oxidergic and cholinergic-nitric oxidergic innervation in porcine middle cerebral arteries. Brain Res 1998; 801: 78–87.
- 20 Goadsby PJ, Uddman R, Edvinsson L. Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Res 1996; 707: 110–8.
- 21 Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ. Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 2001; 53: 221–8.
- 22 Edvinsson L, Jansen I, Cunha e Sa M, Gulbenkian S. Demonstration of neuropeptide containing nerves and vasomotor responses to perivascular peptides in human cerebral arteries. Cephalalgia 1994; 14: 88–96.
- 23 Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides 1992; 13: 527–36.
- 24 Jansen-Olesen I, Goadsby PJ, Uddman R, Edvinsson L. Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. J Auton Nerv Syst 1994; 49 (Suppl.): S97–103.
- 25
Zhu BS,
Blessing WW,
Gibbins IL.
Parasympathetic innervation of cephalic arteries in rabbits: comparison with sympathetic and sensory innervation.
J Comp Neurol
1997; 389: 484–95.
10.1002/(SICI)1096-9861(19971222)389:3<484::AID-CNE9>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 26 Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 1999; 826: 193–9.
- 27 Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–7.
- 28 Hansen J, Sitarz J, Birk S, Rahmann A, Oturai P, Fahrenkrug J et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006; 26: 992–1003.
- 29 IHS. The international classification of headache disorders, 2nd edn. Cephalalgia 2004; 24 (Suppl. 1): 9–160.
- 30 Russell MB, Rasmussen BK, Brennum J, Iversen HK, Jensen RA, Olesen J. Presentation of a new instrument: the diagnostic headache diary. Cephalalgia 1992; 12: 369–74.
- 31 Thomsen LL, Iversen HK, Olesen J. Middle cerebral artery blood flow velocity increases during experimental pressure pain in the head. In: J Olesen, ed. Experimental headache models. New York: Raven Press, 1995: 337–9.
- 32 Thomsen LL, Iversen HK. Experimental and biological variation of three-dimensional transcranial Doppler measurements. J Appl Physiol 1993; 75: 2805–10.
- 33 Nielsen TH, Iversen HK, Tfelt-Hansen P, Olesen J. Small arteries can be accurately studied in vivo, using high frequency ultrasound. Ultrasound Med Biol 1993; 19: 717–25.
- 34 Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126: 241–7.
- 35 Fahrenkrug J, Schaffalitzky de Muckadell OB. Distribution of vasoactive intestinal polypeptide (VIP) in the porcine central nervous system. J Neurochem 1978; 31: 1445–51.
- 36 Fahrenkrug J, Schaffalitzky de Muckadell OV. Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma. J Laboratory Clin Med 1977; 89: 1379–88.
- 37 Pocock SJ. Clinical trials. A practical approach. London: John Wiley and Sons Ltd, 1983.
- 38 Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230–5.
- 39 Lambert GA, Bogduk N, Goadsby PJ, Duckworth JW, Lance JW. Decreased carotid arterial resistance in cats in response to trigeminal stimulation. J Neurosurg 1984; 61: 307–15.
- 40 Gottselig R, Messlinger K. Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex—an experimental model for vascular dysfunctions in cluster headache. Cephalalgia 2004; 24: 206–14.
- 41 Frese A, Evers S, May A. Autonomic activation in experimental trigeminal pain. Cephalalgia 2003; 23: 67–8.
- 42 Maizels M, Geiger AM. Intranasal lidocaine for migraine: a randomized trial and open-label follow-up. Headache 1999; 39: 543–51.
- 43 Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA 1996; 276: 319–21.
- 44 Yarnitsky D, Goor-Aryeh I, Bajwa ZH, Ransil BI, Cutrer FM, Sottile A et al. Wolff award: possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache 2003; 43: 704–14.
- 45 Grant S, Lutz EM, McPhaden AR, Wadsworth RM. Location and function of VPAC (1), VPAC (2) and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries. J Cereb Blood Flow Metab 2006; 26: 58–67.
- 46 Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez del Rio M, Letourneau R et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001; 124: 2490–502.
- 47 Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507–16.
- 48 Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 1999; 162: 4685–96.
- 49 Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann NY Acad Sci 2000; 921: 92–102.
- 50 Bandyopadhyay A, Chakder S, Rattan S. Regulation of inducible and neuronal nitric oxide synthase gene expression by interferon-gamma and VIP. Am J Physiol 1997; 272: C1790–7.
- 51 Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50: 265–70.
- 52 Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 2000; 20: 1205–14.
- 53 Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 2002; 13: 507–9.
- 54 Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M. Passage of vasoactive intestinal peptide across the blood–brain barrier. Peptides 2003; 24: 437–44.
- 55 Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood–brain barrier: therapeutic effects. Curr Pharm Des 2004; 10: 1325–40.
- 56 McCulloch J, Edvinsson L. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. Am J Physiol 1980; 238: H449–56.
- 57 Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia 1995; 15: 109–16.
- 58 Kruuse C, Jacobsen TB, Lassen LH, Thomsen LL, Hasselbalch SG, Dige-Petersen H et al. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab 2000; 20: 1372–9.
- 59 Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 2003; 23: 877–86.
